User login
Key clinical point: Digital breast tomosynthesis plus synthesized 2-dimensional (s2D) mammography was superior to standard digital mammography for the detection of invasive breast cancer (BC).
Major finding: Detection rate of all invasive BC (odds ratio 1.48; P < .0001) was higher with digital breast tomosynthesis+s2D mammography vs digital mammography. None of the adverse events were classified as serious or related to the device used.
Study details: Findings are from the open-label, superiority TOSYMA trial including 99,689 women who were randomly assigned to undergo BC screening with digital breast tomosynthesis+s2D mammography or digital mammography.
Disclosures: This study was funded by Deutsche Forschungsgemeinschaft. Some authors declared running a third-party funded project at the University of Münster or receiving grants, honoraria, or payments from several sources.
Source: Heindel W et al. Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): A multicentre, open-label, randomised, controlled, superiority trial. Lancet Oncol. 2022;23(5):601-611 (Apr 12). Doi: 10.1016/S1470-2045(22)00194-2
Key clinical point: Digital breast tomosynthesis plus synthesized 2-dimensional (s2D) mammography was superior to standard digital mammography for the detection of invasive breast cancer (BC).
Major finding: Detection rate of all invasive BC (odds ratio 1.48; P < .0001) was higher with digital breast tomosynthesis+s2D mammography vs digital mammography. None of the adverse events were classified as serious or related to the device used.
Study details: Findings are from the open-label, superiority TOSYMA trial including 99,689 women who were randomly assigned to undergo BC screening with digital breast tomosynthesis+s2D mammography or digital mammography.
Disclosures: This study was funded by Deutsche Forschungsgemeinschaft. Some authors declared running a third-party funded project at the University of Münster or receiving grants, honoraria, or payments from several sources.
Source: Heindel W et al. Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): A multicentre, open-label, randomised, controlled, superiority trial. Lancet Oncol. 2022;23(5):601-611 (Apr 12). Doi: 10.1016/S1470-2045(22)00194-2
Key clinical point: Digital breast tomosynthesis plus synthesized 2-dimensional (s2D) mammography was superior to standard digital mammography for the detection of invasive breast cancer (BC).
Major finding: Detection rate of all invasive BC (odds ratio 1.48; P < .0001) was higher with digital breast tomosynthesis+s2D mammography vs digital mammography. None of the adverse events were classified as serious or related to the device used.
Study details: Findings are from the open-label, superiority TOSYMA trial including 99,689 women who were randomly assigned to undergo BC screening with digital breast tomosynthesis+s2D mammography or digital mammography.
Disclosures: This study was funded by Deutsche Forschungsgemeinschaft. Some authors declared running a third-party funded project at the University of Münster or receiving grants, honoraria, or payments from several sources.
Source: Heindel W et al. Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): A multicentre, open-label, randomised, controlled, superiority trial. Lancet Oncol. 2022;23(5):601-611 (Apr 12). Doi: 10.1016/S1470-2045(22)00194-2